In the race to develop next-generation respiratory virus vaccines, French pharmaceutical company Sanofi has agreed to buy Vicebio Ltd., a privately-held biotechnology company headquartered in London, UK.
Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, “with potential milestone payments of up to $450 million based on development and regulatory achievements”.
